Glaxosmithkline Biologicals Sa

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Msd Italia S.r.l.

Nouscom Ag

Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Sabin Vaccine Institute

Oxford University Innovation Limited

Stefano Colloca

Alfredo Nicosia

Riccardo Cortese

Virginia Ammendola

Antonella Folgori

Armin Lahm

Gary J Nabel

Cheng Cheng

Nancy J Sullivan

Alessandra Vitelli

Stefania Capone

Clement Asiedu

Maria Ambrosio

Rossella Merone

Andrew J Bett

David C Kaslow

John W Shiver

Emilio A Emini

Alessandra Luzzago

Elisabetta Sporeno

Agostino Cirillo

Bruno Bruni Ercole

Annalisa Meola

Fabiana Grazioli

Elisabetta (deceased) Sporeno

Gennaro Ciliberto

Adrian Vivian Hill

Nicola La Monica

Arturo Reyes

Benjamin Wizel

Geraldine O'Hara

Paolo Palazzolo, Legal Representative

Alfreda Nicosia

A simian adenoviral vector comprising two expression cassettes, wherein each expression cassette comprises a transgene and a promoter, and wherein the first expression cassette is inserted in the E1 region of the simian adenoviral vector, and the second expression cassette is inserted in a region of the adenoviral vector that is compatible with vector replication.

Simian adenoviral vectors with two expression cassettes

This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).

Chimpanzee adenoviral vector-based filovirus vaccines

An adenoviral vector comprising two expression cassettes, wherein each expression cassette comprises a transgene and a promoter, and wherein each transgene encodes an RSV antigenic protein or a fragment thereof.

Adenoviral vectors with two expression cassettes encoding RSV antigenic proteins or fragments thereof

The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.

Adenovirus polynucleotides and polypeptides

Simian adenovirus vectors comprising the ChAd-157 fiber protein

The present invention relates to a cell line, use of the cell line and a method for producing infectious viral particles using said cell line.

Eukaryotic cell line

A new promoter comprising: (i) an hCMV enhancer sequence; (ii) an hCMV promoter sequence; (iii) a splice donor region; (iv) a cell-derived enhancer sequence; and (v) a splice acceptor region.

Enhanced promoter

The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.

Poxviral vaccines

Replication competent simian adenoviral vectors are provided for the delivery of exogenous immunogens. Vectors of the invention demonstrate superior replication and expression of exogenous immunogens. They are useful as prophylactic and therapeutic vaccines as well as in gene therapy.

Replication competent adenoviral vectors

There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of:

There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and(c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.

The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polynucleotides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.

Recombinant simian adenoviral vectors encoding a heterologous fiber protein and uses thereof

The present invention relates to novel adenovirus strains with a high immunogenicity and no pre-existing immunity in the general human population. The lack of pre-existing immunity is due to novel hypervariable regions in the adenoviral capsid protein hexon. The novel adenovirus strains also have an improved capacity for reproduction. The present invention provides nucleotide and amino acid sequences of these novel adenovirus strains, as well as recombinant viruses, virus-like particles and vectors based on these strains. Further provided are pharmaceutical compositions and medical uses in the therapy or prophylaxis of a disease, and methods for producing an adenovirus or virus-like particles utilizing the novel sequences, recombinant viruses, virus-like particles and vectors.

Non human great apes adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof

Growing community of inventors

Rome, Italy

Stefano Colloca